TY - JOUR
T1 - Neuroleptic malignant syndrome
AU - Ingall, T. J.
AU - Tennant, C.
PY - 1986
Y1 - 1986
N2 - The neuroleptic malignant syndrome is a relatively rare but potentially fatal complication of the use of major tranquilizers; mortality may be as high as 20%. The syndrome is manifest by the onset of hyperpyrexia, muscular rigidity and tremor, impaired consciousness and autonomic dysfunction. The pathophysiology is thought to be by way of dopamine receptor blockade. The syndrome is managed by cessation of the neuroleptic medication, by supportive measures and by instituting treatment with one or more of a number of specific drugs whose use is based on theoretical considerations rather than empirical evidence of efficacy; these drugs include anticholinergics, L-dopa, bromocriptine amantidine and dantrolene sodium. Although not proven, early recognition and treatment may reduce both the mortality and the longer term morbidity of this syndrome.
AB - The neuroleptic malignant syndrome is a relatively rare but potentially fatal complication of the use of major tranquilizers; mortality may be as high as 20%. The syndrome is manifest by the onset of hyperpyrexia, muscular rigidity and tremor, impaired consciousness and autonomic dysfunction. The pathophysiology is thought to be by way of dopamine receptor blockade. The syndrome is managed by cessation of the neuroleptic medication, by supportive measures and by instituting treatment with one or more of a number of specific drugs whose use is based on theoretical considerations rather than empirical evidence of efficacy; these drugs include anticholinergics, L-dopa, bromocriptine amantidine and dantrolene sodium. Although not proven, early recognition and treatment may reduce both the mortality and the longer term morbidity of this syndrome.
UR - http://www.scopus.com/inward/record.url?scp=0022898026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022898026&partnerID=8YFLogxK
U2 - 10.5694/j.1326-5377.1986.tb113872.x
DO - 10.5694/j.1326-5377.1986.tb113872.x
M3 - Article
C2 - 3773831
AN - SCOPUS:0022898026
SN - 0025-729X
VL - 145
SP - 454
EP - 455
JO - Medical Journal of Australia
JF - Medical Journal of Australia
IS - 9
ER -